{"title":"Correction: B107-14 Azd0292, a Novel Investigational Fc-engineered Humanized Monoclonal Antibody for Bronchiectasis With Chronic Pseudomonas Aeruginosa Colonization: Results From a Randomized Phase I Study in Healthy Adults.","authors":"","doi":"10.1093/ajrccm/aamag475","DOIUrl":"https://doi.org/10.1093/ajrccm/aamag475","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":" ","pages":""},"PeriodicalIF":21.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Brensocatib is approved for adults and adolescents with bronchiectasis","authors":"James D Chalmers","doi":"10.1093/ajrccm/aamag543","DOIUrl":"https://doi.org/10.1093/ajrccm/aamag543","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":"13 1","pages":""},"PeriodicalIF":24.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Edward T Qian,Emma J Graham Linck,Alexandra B Spicer,Kevin G Buell,Jonathan D Casey,Kevin P Seitz,Wesley H Self,Li Wang,Adam Wright,Todd W Rice,Matthew W Semler,Matthew M Churpek,for the Evidence-based Individualized Treatment Effects (EvITE) Group and the Pragmatic Critical Care Research Group
{"title":"Individualized Treatment Effects of Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection","authors":"Edward T Qian,Emma J Graham Linck,Alexandra B Spicer,Kevin G Buell,Jonathan D Casey,Kevin P Seitz,Wesley H Self,Li Wang,Adam Wright,Todd W Rice,Matthew W Semler,Matthew M Churpek,for the Evidence-based Individualized Treatment Effects (EvITE) Group and the Pragmatic Critical Care Research Group","doi":"10.1093/ajrccm/aamag544","DOIUrl":"https://doi.org/10.1093/ajrccm/aamag544","url":null,"abstract":"Abstract Rationale Among adults hospitalized with acute infection, a recent randomized trial observed no significant average treatment effect of cefepime versus piperacillin-tazobactam on acute kidney injury or death, but fewer days-alive-and-free-of delirium and coma with cefepime. Objectives To determine whether patients’ individual characteristics modify the effect of cefepime versus piperacillin-tazobactam on outcomes. Methods In this secondary analysis of the Antibiotic Choice On Renal Outcomes (ACORN) trial, an effect model was derived and validated to predict the effect of cefepime versus piperacillin-tazobactam for adults hospitalized with acute infection. The primary outcome was survival without acute kidney injury; the secondary outcome was survival without delirium or coma. Measurements and Main Results The individualized treatment effect predicted in the validation cohort significantly modified the effect of cefepime versus piperacillin-tazobactam on survival without acute kidney injury (Qini 1.68; 95% confidence interval [CI], 0.25-3.18; p-value = 0.01). Among 626 patients predicted to experience ≥5% benefit from cefepime, 81.2% of patients randomized to cefepime survived without acute kidney injury, versus 74.2% randomized to piperacillin-tazobactam (difference, 7.1%; 95%CI, 0.25 to 13.9%). Among 203 patients predicted to experience ≥5% benefit from piperacillin-tazobactam, 56.6% of patients randomized to cefepime survived without acute kidney injury, versus 63.0% randomized to piperacillin-tazobactam (difference, -6.3%; 95%CI, -20.7 to 8.2%). The effect of trial group on survival without delirium or coma was not modified by individual characteristics. Conclusions Patients’ individual characteristics modified the effect of cefepime versus piperacillin-tazobactam on survival without acute kidney injury but not on survival without delirium or coma.","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":"30 1","pages":""},"PeriodicalIF":24.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael D April,Harris Butler,Steven G Schauer,Adit A Ginde
{"title":"Reply to Wang\u0000 et al.\u0000 : Does absolute milligram exposure confound high-dose rocuronium efficacy in the critically ill?","authors":"Michael D April,Harris Butler,Steven G Schauer,Adit A Ginde","doi":"10.1093/ajrccm/aamag541","DOIUrl":"https://doi.org/10.1093/ajrccm/aamag541","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":"32 1","pages":""},"PeriodicalIF":24.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}